Investor Presentaiton
Growth levers for the future - UK business
Revenue FY21
Wide UK customer base and
100% reach within the
distribution channel
Broad and diversified range
of product portfolio with
well recognized brands
Captured a large share of
OTC and generic markets
Organic Growth
Working on receiving USFDA
approval for the Southport
facility to commence
exports to the USA
Increase in partnerships
with major national
distributors, pharmacies,
retailers and chemist
wholesalers
New Products in Pipeline
Developed a range of
narcotic & dermatology
products
Range of oral solid products
under development to
increase market share in
generic and OTC markets
Investment in
manufacturing facility to
develop oral liquid solutions
Inorganic Growth
For rapid expansion into
various therapy areas and
other markets such as in the
UK and in Europe, the
Company plans to acquire
product licenses
Revenue FY25
■ Sustainable revenue growth
Consistently delivering on
profit margins
Focus on Europe, USA and
other export destinations
One of the key OTC product
supplier and private label
manufacturer in the
industry
©2021 - Marksans Pharma Limited, All Rights Reserved.
88
28View entire presentation